Funding for this research was provided by:
National Institutes of Health (R01CA219836, R01CA242003, R21CA223371, R01CA241191, R01CA211963)
Received: 26 May 2020
Accepted: 23 June 2020
First Online: 27 July 2020
Ethics approval and consent to participate
: Not applicable.
: This study does not include any individual person’s data in any form.
: Y.H., S.K., X.Z, X.L., G.Z., and D.Z. are inventors of two pending patent applications for use of Bcl-xL PROTACs as senolytic and antitumor agents. G.Z., and D.Z. are co-founders of and have equity in Dialectic Therapeutics, which develops Bcl-xL PROTACs to treat cancer. The remaining authors declare no competing financial interests.